Dolutegravir‐induced acquired sideroblastic anemia in a HIV positive patient: A challenging hematologic complication

Key Clinical Message Dolutegravir, the most recent antiretroviral drug with high efficacy, good tolerability, infrequent drug–drug interactions, and a favorable safety profile has not been reported in current literature as a cause of acquired sideroblastic anemia. Here, we present a 35‐year‐old male...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 11; no. 12; pp. e8301 - n/a
Main Authors Dhonju, Kiran, Gautam, Ashmita, Dahal, Abhinav, Sharma, Niraj Kumar, Adhikari, Divas, Devkota, Lina, Adhikari, Prabhat, Tuladhar, Sampurna, Pathak, Bishnu Deep, Banmala, Sabin
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.12.2023
John Wiley and Sons Inc
Wiley
Subjects
acquired sideroblastic anemia
adverse drug reaction
Anemia
Biopsy
Bone marrow
Case Report
Congenital diseases
Dolutegravir
Drug dosages
Drug therapy
Hematology
HIV
Human immunodeficiency virus
Hyperplasia
Infectious Diseases
Iron
Mitochondria
Myelodysplastic syndromes
Naranjo scale
Virology
HIV
acquired sideroblastic anemia
adverse drug reaction
Naranjo scale
Dolutegravir
Online AccessGet full text

Cover

More Information
Summary:Key Clinical Message Dolutegravir, the most recent antiretroviral drug with high efficacy, good tolerability, infrequent drug–drug interactions, and a favorable safety profile has not been reported in current literature as a cause of acquired sideroblastic anemia. Here, we present a 35‐year‐old male patient who was diagnosed with acquired sideroblastic anemia to Dolutegravir therapy.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Report-1
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.8301